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ABSTRACT
Polyamines are essential for life and are associated with cell cycle and
development. Excess polyamine production occurs during tumor formation and is one
possible target for chemopreventative and chemotherapeutic treatm ent. One enzyme,
ornithine decarboxylase (ODC), plays a key role in polyamine biosynthesis. Among
other regulators, the protein antizyme (Az) limits polyamine levels in the cell. It binds
ODC and renders it unable to produce polyamines. The mechanism by which ODC and
Az interact is unknown and is explored in this study.
It is known that ODC and Az have high affinity for one another, but the reason
for the basal level of ODC activity that remains in excess Az in assays is unclear.
Varying the tem perature and coenzyme concentrations in an assay revealed that these
factors successfully changed the level of ODC activity at which the two proteins ceased
to bind. The persistence of ODC activity in excess Az under several assay conditions
showed that the remaining activity is not a result of the methods by which the assay is
prepared. The mechanism by which some ODC activity is allowed to rem ain in excess
Az remains uncertain.
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Modern cancer research explores a great diversity of biochemical pathways in
the hopes of developing more effective chemotherapeutic and chemopreventative
drugs. One promising area of research explores the roles of polyamines and the
substances that regulate them as potentially effective mechanisms for treating cancer.
Understanding their function, biosynthesis, transport, and catabolism in both healthy
and cancerous ceils is key. It is also helpful to investigate the ways in which some
regulators affect the development and inhibition of these compounds in vitro and in vivo
in clinical trials. Further exploration in the less understood mechanisms of polyamine
control could yield improved chemotherapy for patients and chemoprevention in highrisk groups.
Polyamines, including putrescine, spermidine and spermine, are essential for life
and are associated with cell cycle and development. They are nutritive to normal cells
and enable the increased growth of cancerous cells by promoting proliferation,
differentiation and immortalization (Cohen 1998, Nishioka 1996). The polyamines are
involved with ribosome function and protein synthesis, maintenance including apoptosis,
and angiogenesis (Cohen 1998, Nishioki, et al 1996). In addition, spermidine is
connected with the formation of hypusine, an amino acid that is necessary for protein
synthesis in yeast and animal cells (Cohen 1998). It has also been discovered that
reduced cellular polyamine levels decrease the rate of virus multiplication (Cohen
1998). Clearly, polyamines serve key functions in the growth and maintenance of both
normal and unhealthy cells.
Polyamines become available to cells by two means: they are either synthesized
within the cells or they are consumed by an organism and then transported into the

cells. As shown in Figure 1, ornithine decarboxylase (ODC) converts ornithine to the
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first polyamine putrescine in the rate-limiting step of polyamine synthesis. ODC is
activated by GTP and is inhibited by a number of compounds including the protein
antizyme (Az). ODC catalyzed biosynthesis of polyamines is limited by a feedback
control mechanism. The presence of high levels of polyamines promotes translation of
Az mRNA, creating a feedback loop in which polyamines that are synthesized inhibit
further production of polyamines (Almrud 2000), as shown in Figure 1. ODC is a protein
with an extremely short half-life, only about 20 minutes. Its short half-life and the
diversity of conditions that strongly alter its activity indicate that its activity is highly
controlled.
Figure 1: The Polyamine Biosynthetic Pathway

Az binds active ODC and renders it unable to produce polyamines. Az serves to
inhibit ODC by binding it in its monomeric (unpaired) state, enabling conformational
changes in ODC that expose its C terminus. The exposed C-terminus of the ODC
allows it to be degraded by the 26S proteosome (Almrud 2000, Persson 1996). This
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idea is supported by the fact that ODC truncated at the C-terminus has a significantly
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longer half-life (Persson 1996). Given that high levels of polyamines are present in
cancerous cells, Az provides one opportunity for chemopreventive and
chemotherapeutic research.
While Az inhibits excessive cell growth and differentiation by inhibiting polyamine
synthesis within the cell, it may also serve to limit polyamine levels by interfering with
the polyamine transporter. Polyamines originate from the food consumed by an
organism are transferred from the gastrointestinal tract to the cell. They can
supplement the needs of cells that have become unable to synthesize sufficient
amounts of polyamines “due to lack of substrates or to inhibition of ODC” (Persson
1996). Transporter activity is stimulated by growth promoting agents, another group of
compounds that are present in high levels in cancerous cells. Reducing the effects of
growth promoting agents with Az in these cells could decrease the rate of cancerous
growth.
The transporter is active during periods in which cells are deprived of polyamine
synthesis. It is inactive when polyamines are present or in excess (Persson 1996). It is
thought “that elevations in cellular polyamine levels stimulate the production of a labile
protein that reversibly inactivates the polyamine transporter” (Mitchell 1994). Further
evidence suggests that feedback response noted in polyamine transport may share a
common intermediate with the response resulting in ODC instability (Mitchell 1994).
This implies that Az is one mechanism of transporter control. The mechanism by which
Az inhibits polyamine transport remains unknown.

\mf/
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While a cell can limit polyamine production and transport into the cell, it must also
W

retain the ability to catabolize polyamines. Polyamine catabolism can consist of
regression to a polyamine earlier in the metabolic pathway, acetylation for excretion,
break-down into amino acids, or oxidation of putrescine for the formation of GABA, a
neurotransmitter. Spermidine spermine acetyl transferase (SSAT), another wellregulated enzyme, acetylates its products and can convert spermine to spermidine and
spermidine to putrescine. Polyamines “created” by SSAT can continue through
metabolism or be excreted. The transacetylated product polyamines are far more easily
excreted that their non-acetylated counterparts. SSAT is induced under conditions
where a cell acquires high levels of polyamines due to toxins, hormones or the
polyamines themselves (Persson 1996).
The polyamines may be catabolized into amino acids via a variety of pathways.

^

One such example is the indirect relationship between putrescine, glutamate and
ornithine, shown in Figure 2. Interestingly, putrescine catabolism to amino acids occurs
more frequently in aged cells than younger ones (Cohen 1998). This infers that there is
some relationship between polyamine control mechanisms and senescence. One
possible explanation is that older cells have increased amine oxidases (Cohen 1998).
As previously mentioned, putrescine can be converted into the inhibitory
neurotransmitter GABA. The transformation can occur in both the brain and
peripherally. The putrescine to GABA change is essentially the result of an oxidase,
followed by an aldehyde dehydrogenase (Cohen 1998).
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Figure 2: An Overview of Polyamine Metabolism
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Figure from Cohen (1998).
Neoplastic transformation, or the immortalization of cells, is linked with abnormal
polyamine metabolism. Changes in polyamine synthesis, degradation, and excretion
can be demonstrative of cancer (Cohen 1998). Evidence indicative of this association
includes:
1. Increased excretion of polyamines by many cancer patients
2. Correlation of ODC content to the growth rates of certain cancers
3. Correlation of cellular ODC and polyamines to the growth rates of some tumor
cells
4. Some effective cancer therapies decrease “abnormally high rates of
polyamine synthesis” (Cohen 1998).
w
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Excess polyamine production occurs during tumor formation and slows with cancer
remission. Because excessively high levels of polyamines have been associated with
cancer, an opportunity has arisen for study into possible improvements in cancer
diagnosis and chemotherapeutic or chemopreventative treatments involved with this
pathway.
Increased ODC-catalyzed biosynthesis of polyamines can contribute to
cancerous growth. The protooncogene c-myc enhances ODC transcription, resulting in
increased levels of polyamine synthesis. This augmentation of polyamine synthesis is
one characteristic of cancerous cells (Cohen 1998). ODC is associated with
proliferation and hyperplasia (increased number of cells) (Cohen 1998) and its levels
can correlate with malignancy. The strong correlation between ODC activity and cancer
suggest that testing of ODC activity levels could be used to help diagnose cancers and
that the polyamine biosynthetic pathway provides an excellent target for new
chemotherapeutic and chemopreventative practices.
Regulation of polyamine levels must be highly controlled under normal conditions
by the short-lived proteins ODC, SSAT and others. One mechanism by which excess
polyamines contribute to cancerous growth is via constitutively active ODC. This ODC
is no longer regulated, synthesizing polyamines without bound after the cell has been
“transformed by carcinogens, viruses or oncogenes” (Almrud 2000). For this reason,
substances that inhibit ODC activity could be productively explored in a laboratory
setting. This inhibition could arise from “regulation of ode transcription, posttranslational modification of ODC and negative feedback control” (Almrud 2000).

The close relationship between polyamine level control and cancer enable
exploration into the development of clinically relevant improvements in the
understanding of cancer. One such application is the advancement of clinical testing for
cancer. Given the strong association of elevated polyamine levels in urine and red
blood cells and cancer, it is possible that these levels could reveal the degree to which
the cancer has advanced in a patient. (Cohen 1998). ODC activity could also be used
to detect cancer. Increased activity was detected in “normal-appearing colonic mucosa
. . . in patients with familial polyposis” over that which was present in controls (Nishioki,
et al 1996). This clinical trial indicates that the characteristic can be used as an
effective biological marker for cancer. The efficacy of testing ODC activity as a marker
in other organs is supported by similar results (Nishioki, et al 1996).
Inhibiting polyamine biosynthesis may also be used in chemotherapy of cancer.
A number of clinical studies targeting the pathway involved in polyamine biosynthesis
have already begun, using polyamine analogs and other compounds. Eflornithine
(DFMO) and methylglyoxyl-bis(guanylhydrazone) (MGBG) are two such potential
chemotherapeutic agents. These agents are specifically targeted against ODC and a
similar enzyme, AdoMetDC, respectively.
DFMO irreversibly inhibits ODC and leads to depletion of polyamines in the cells.
Clinical studies involving DFMO have consisted of chemoprevention trials, anti
trypanosomal therapy, and treatment of brain tumors and cervical dysplasia. (Nishioki
154). While successfully reducing putrescine and spermidine levels, its effects on
spermine levels are limited. “Limited clinical evaluation against solid tumors” in the
1980s were unsuccessful “due to a lack of potency” (Kramer 1996). Later studies have

established its ability to limit polyamine synthesis in vitro and in vivo. Patients’ cancers
did not enter remission, but some were stabilized and levels of circulating blast cells
decreased in some of the patients (Nishioki, et al 1996). The side effects of DFMO
treatment are nontoxic, relatively low and are reversible.
MGBG causes the inhibition of AdoMetDC, another polyamine biosynthetic
enzyme. It serves to block spermidine synthesis, thereby reducing Az and
subsequently increasing ODC activity. Clinical studies involving MGBG have dealt with
non-Hodgkins lymphoma in AIDS patients. Clinical trials involving MGBG were initially
unsuccessful because the compound remained in tissues for extended periods of time.
Some of MGBG’s undesired effects include disruption of mitochondrial structure and
function (Kramer 1996). However, it can be very effective against certain cancers,
including non-Hodgkins lymphoma (Nishioki et al 1996). MGBG analogs that are more
specific, and are therefore less likely to produce toxic side effects, have also been
developed. One example of an MGBG analog with reduced potential side effects is
CGP-48664. It binds ODC as a competitive inhibitor using an alternative transport
mechanism and provides another opportunity for improved chemotherapeutic treatment.
The polyamine biosynthetic pathway has also been explored for the development
of chemopreventative agents. Trials consisting of DFMO (the irreversible inhibitor of
ODC) treatment to prevent cancer have been performed on animals that have been
exposed to cancer-causing agents. The results were positive and clinical trials in
humans have yielded similarly promising results with relatively low levels of side effects
(Nishioki et al 1996). In a similar way, polyamine analogs may also prove to be effective
in chemoprevention (Nishioki et al 1996).

Az provides another key opportunity for chemotherapeutic and
W /

chemopreventative treatment. Where DFMO only blocks ODC-catalyzed polyamine
biosynthesis, Az would be expected to inhibit both ODC activity and polyamine transport
into the cells. This indicates that Az could more efficiently cause polyamine deficiency
in affected cells, creating an environment in which cancerous growth would be inhibited.
Further research into the role of Az in ODC inhibition and polyamine transport will
provide the knowledge necessary to develop Az into a clinically effective
chemotherapeutic and/or chemopreventative agent.
One aspect of Az inhibition of ODC that remains unclear is the mechanism by
which Az binds ODC. While it is clear that Az and ODC have high affinity for one
another, assays reveal a basal level of ODC activity that remains in excess Az.
Understanding the mechanism by which some ODC activity is able to remain in excess

V

Az could reveal new questions in the development of Az as a chemopreventative agent.
Varying the conditions under which the assay is performed should elucidate the roles
that different factors play in controlling the level of ODC activity at which ODC and Az
cease to bind.
In this study, the most favorable conditions for ODC-Az interaction have been
explored. A fixed amount of ODC was prepared to which increasing amounts of Az
were added to excess. The amount of ODC activity was recorded and losses in ODC
activity were attributed to interaction with Az, thereby revealing Az activity. This Az
activity is compared across variables (temperature and presence or absence of
coenzyme), with the highest level of Az activity indicating optimal assay conditions for
ODC-Az interaction.

w
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To perform the assay, HTC (rat hepatoma) cells were first induced with
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methylglyoxyl-bis(guanylhydrazone) (MGBG) and dicyclohexylamine (DCHA). These
cells were used to provide the ODC activity. Other HTC cells were induced for Az using
putrescine, making use of the feedback repression of ODC by polyamines. Graded
amounts of Az were incubated with the ODC on ice for 15 minutes in buffer. After this
reaction period the level of active ODC was determined by a UC release assay. 14Clabelled ornithine was added to the reaction vials. Filter paper that was treated with
KOH was placed into the reaction vial stoppers. The KOH on the paper captured the
14C-labelled product C 02during incubation After the stopper had been placed onto the
reaction vial, the mixture was incubated and shaken at 37°C for one hour. Citric acid
was injected into the vials to stop the reaction. The mixture was then incubated and
shaken for 30 minutes. Following the assay, the filter paper was placed in scintillation
fluid. The disintegrations of the 14C-label were expressed as the emission of light that
was counted (in counts per minute) by a liquid scintillator. The radioactivity counted by
the scintillator revealed the levels of ODC activity remaining and consequently the level
of Az activity.The experimental conditions were varied in temperature (4° and 37°) and
presence of absence of the coenzyme, pyridoxal phosphate (PLP). Temperature was
expected to play a role in the level of Az activity because it affects the availability of
ODC to interact. ODC remains homodimeric (paired ODC molecules) at 37°, but
becomes monomeric (unpaired, open for interaction) at 4°. The addition of PLP, a
coenzyme that promotes the formation of ODC dimers, should have decreased ODC
inactivation by Az. A combination of these conditions should have revealed if the
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remaining ODC activity in excess Az was a result of the methods by which the assay
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was prepared.
Figure 3: Levels of ODC Inactivation
ODC-Az Interaction

Assay results revealed that the conditions under which the assay was prepared
did play an important role in the level of ODC activity that remained in excess Az, as
shown in Figure 3. The assays demonstrated that Az was able to inactivate more ODC
at 4° than at 37°, as expected. Performing the assay at 4° allowed the ODC to remain in
its monomeric state, which made it more readily available to promote polyamine
synthesis. Under physiologic conditions (37°), the ODC should have been dimeric and
would be expected to not be as susceptible to Az binding. The addition of PLP provided
a similarly predictable result. Given that PLP is a coenzyme that encourages the
formation of ODC dimers, it too decreased observed Az activity. While the variables
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successfully changed the activity level at which ODC-Az interactions ceased, they could
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not entirely eliminate the enduring ODC activity.
The levels of ODC activity at which ODC and Az cease to bind varied from about
65% of original activity (for the assay performed with PLP at 37°) to about 90% (for the
assays performed at 4°). The fact that at least 10% of ODC activity was able to remain
under all of the assay conditions explored indicates that the remaining activity is not a
result of the methods by which the assay is prepared. The mechanism by which some
ODC activity is allowed to remain in excess Az remains unclear. Though it is clear that
Az is unable to completely inactivate ODC under various assay conditions, its function
under normal physiologic conditions remains very important. Further inquiry will be
needed to reveal more about how Az binds ODC and to discover what enables ODC
activity to remain in excess Az.

^

Continuing research of the interactions between Az and ODC should elucidate
more about polyamine synthesis, inhibition and transport. Given the strong link
between excessive polyamines and cell transformation and immortalization, repression
of polyamine synthesis and transport into the cell could limit cancerous growth. Az
serves as an effective inhibitor of both ODC-catalyzed polyamine synthesis and
polyamine transport into cells. This combination is not shared by other compounds in
the polyamine pathway, some of which have already proven successful in clinical trials.
Using what is already known about these other regulators in the pathway as a
background, learning more about Az inhibition of high levels of polyamines be helpful in
establishing Az as a safe, effective chemotherapeutic and chemopreventative agent.
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